These antitumor effects have been mechanistically linked to the activation of tumor suppressors and stress-response pathways, including p53 and CHOP/ATF4, as well as the inhibition of pro-oncogenic signaling cascades such as GPR55/MAPK and the tumor glycolytic metabolism. The gene discussed is DDIT3; the disease is neoplasm.